Investment Considerations Co-Diagnostics is developing a proprietary PCR platform designed to expand access to gold-standard molecular diagnostics in decentralized and point-of-care environments. The company’s Co-Primers™ technology is designed to enhance specificity and enable efficient multiplex testing across a range of infectious disease applications. Its product pipeline includes at-home and point-of-care diagnostic platforms that, if approved, … Continue reading “Co-Diagnostics Inc. (NASDAQ: CODX)”
| Symbol | Release | Time |
|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |